X-ray lightsource at DESY identifies promising candidates for COVID drugs
Electron density map of the most antiviral active ingredient calpeptin (yellow) binding at the main protease. © DESY/Sebastian Günther
At DESY's high-brilliance X-ray light source PETRA III, a team from more than 30 research institutions has identified several candidates for active substances against the coronavirus SARS-CoV-2. They bind to an important protein of the virus and could thus be the basis for a drug against Covid-19. The MX team from HZB examined part of the measurement data with special analysis algorithms in order to identify suitable active substances. The study has now been published in the renowned journal Science.
In a so-called X-ray screening, the researchers, under the leadership of DESY, tested almost 6000 known active substances that already exist for the treatment of other diseases in a short amount of time. After measuring about 7000 samples, the team was able to identify a total of 37 substances that bind to the main protease (Mpro) of the SARS-CoV-2 virus, as the scientists report online today in the journal Science. Seven of these substances inhibit the activity of the protein and thus slow down the multiplication of the virus. Two of them do this so promisingly that they are currently under further investigation in preclinical studies. This drug screening – probably the largest of its kind – also revealed a new binding site on the main protease of the virus to which drugs can couple.
“The active substances Calpeptin and Pelitinib clearly showed the highest antivirality with good cell compatibility. Our cooperation partners have therefore already started preclinical investigations with these two substances,” explains DESY researcher Sebastian Günther, first author of the Science publication.
In addition to DESY scientists, researchers from the Universities of Hamburg and Lübeck, the Bernhard Nocht Institute for Tropical Medicine, the Fraunhofer Institute for Translational Medicine and Pharmacology, the Heinrich Pette Institute, the European XFEL, the European Molecular Biology Laboratory EMBL, the Max Planck Society, the Helmholtz-Zentrum Berlin and other institutions are involved in the work.
Note: This is a shortened version of the full text of the press release published at DESY Website.
- Surprising insights into the chemistry of hydroxyl radicals at BESSY IIHow do radicals form in aqueous solutions when exposed to UV light? This question is important for health research and environmental protection, for example with regard to the overfertilisation of water bodies by intensive agriculture. A team at BESSY II has now developed a new method of investigating hydroxyl radicals in solution. By using a clever trick, the scientists gained surprising insights into the reaction pathway.
- Theory meets practice – We’re heading back to HTW Berlin!The HZB’s BIPV consultancy office (BAIP) is once again coordinating and delivering the lecture series “Building-Integrated Photovoltaics”.
- AI-driven Catalyst Discovery: €30 million funding for German consortiumSix partners from research and industry, including Helmholtz-Zentrum Berlin (HZB), the Fritz-Haber-Institute of the Max Planck Society (FHI), BASF, Dunia Innovations, Siemens Energy, and the Technical University Berlin are launching a joint project to accelerate the catalyst discovery. The German Federal Ministry for Science, Technology and Space (BMFTR) is providing €30 million in funding for ASCEND (Accelerated Solutions for Catalysis using Emerging Nanotechnology and Digital Innovation). The research initiative targets the defossilisation of energy-intensive industries while safeguarding industrial competitiveness, with a focus on the chemical sector. The five-year project will start on 1st April 2026.